An SK Group-backed AI startup, PhynX Lab, has launched South Korea’s first generative AI platform tailored specifically for the pharmaceutical industry. Named Cheiron, the platform is designed for professionals such as researchers and pharmacists, offering advanced tools to streamline drug discovery, clinical trials, and production processes. Developed by PhynX Lab, a Silicon Valley-based venture under SK Networks, Cheiron aims to save time and resources while boosting efficiency.
At the core of Cheiron is Modular RAG (Retrieval-Augmented Generation), an innovative technology that enhances search capabilities and information generation. Cheiron is expected to transform the pharmaceutical landscape by integrating flexibility and precision and position South Korea as a global leader in AI-driven healthcare advancements.
Cheiron, PhynX Lab’s flagship generative AI platform, offers several key features designed to transform the pharmaceutical industry. It uses a one-stop, semantic-based search system that simplifies the search for relevant information across multiple sources, including academic databases like PubMed, general search engines, and internal corporate documents.Â
By leveraging its Modular RAG framework, Cheiron can retrieve and generate answers quickly and accurately, tailored to specific user needs, making it a powerful tool for pharmaceutical professionals.
At the heart of Cheiron’s functionality is its Modular RAG technology, which enhances the capabilities of traditional Retrieval-Augmented Generation. This advanced framework allows the platform to gather data from various databases and generate responses based on natural language processing.Â
It can verify information autonomously and ensure the accuracy of responses, addressing the common problem of unreliable data often seen in conventional AI systems. This feature makes Cheiron especially valuable for complex pharmaceutical tasks like drug discovery and clinical trial design.
PhynX Lab has also emphasized Cheiron’s flexibility and scalability. The platform’s modular design allows it to adapt to new technologies and data types, offering both standalone and interconnected functionalities.Â
Like Lego blocks, its modules can be easily linked together or operate independently, making it highly customizable for different organizational needs. Additionally, Cheiron’s framework ensures enhanced data security by optimizing the storage selection process.
Cheiron’s benefits extend beyond search capabilities. The platform also automates workflows, streamlining tasks like data organization and document creation. This automation can significantly reduce the time spent on administrative tasks, allowing pharmaceutical professionals to focus more on research and development. PhynX Lab has also ensured that Cheiron supports multiple languages, expanding its usability across global markets.
CEO Bae Min-seok highlighted the platform’s ability to cut down document search time by up to 80% compared to traditional methods, based on findings from user tests. The platform’s success in this area could substantially speed up the research planning stage, positioning Cheiron as a game-changer for the industry. PhynX Lab plans to refine the platform’s capabilities further while targeting a broader customer base within the pharmaceutical sector.
Cheiron’s launch marks a pivotal moment in AI’s integration into the pharmaceutical industry, democratizing access to cutting-edge tools that were previously limited to large-scale organizations. With its advanced capabilities, even smaller research teams can now harness the power of AI to accelerate drug discovery and development, reducing the time and costs traditionally associated with these processes. This shift enables faster innovations, opening the door for collaborative efforts that can potentially lead to lifesaving treatments being developed at unprecedented speeds.
